Immunome (IMNM) CFO Max Rosett Sells 60,000 Shares

Max Rosett, the Chief Financial Officer of Immunome, Inc., sold 60,000 shares of the company on June 15, 2026. The shares were sold at an average price of $18.23, making the transaction worth approximately $1.09 million. This sale was part of a planned trading arrangement.

Other Institutional Activity in Immunome

FMR LLC grew its holdings in Immunome by 420,238 shares, ending with 16,969,954 shares valued at about $371.1 million. T. Rowe Price Investment Management, Inc. added 2,942,024 shares, bringing its total to 16,364,011 shares worth approximately $357.9 million. BlackRock, Inc. increased its position by 573,678 shares, now holding 8,168,674 shares valued at $178.6 million. Meanwhile, Redmile Group, LLC reduced its holdings by 159,500 shares, leaving it with 5,558,885 shares worth around $121.6 million.

Immunome, Inc. Stock Down 22.7%

Shares of Immunome (NasdaqCM:IMNM) recently traded at $17.91. The company has a market capitalization of roughly $2.03 billion. Although it has no meaningful P/E ratio due to its lack of profitability, the stock has a beta of 2.07, indicating higher volatility. Immunome's 52-week trading range is between $7.96 and $27.65. The 50-day moving average is $21.68, while the 200-day moving average stands at $19.25. The firm maintains a strong liquidity position with a current ratio of 21.68 and a quick ratio of 21.26, alongside a debt-to-equity ratio of 0.63.

Recent Earnings

Immunome reported revenue of $4.02 million, with a net margin of 0.0% and a return on equity of -50.1%. The company is expected to announce its next earnings on August 6, 2026.

Insider Buying and Selling at Immunome, Inc.

On June 15, 2026, Max Rosett, Immunome's CFO, sold 60,000 shares at $18.23 each, totaling $1.09 million, in a planned transaction. On the same day, he also acquired 60,000 shares at $1.05 each. Earlier, on June 10, 2026, insiders including James Boylan, Jean Jacques Bienaime, and Isaac Barchas each purchased 9,897 shares.

Analysts Set New Price Targets

On June 12, 2026, Wedbush reiterated its 'buy' rating for Immunome with a $31 price target. Previously, on May 28, 2026, Truist Securities and Barclays both maintained 'buy' ratings with targets of $37 and $36, respectively. The consensus among 13 analysts is a 'strong buy', with a mean target price of $35.77.

About Immunome, Inc.

Immunome, Inc. is a biotechnology company based in Bothell, Washington. It focuses on discovering and developing antibody-drug conjugates and other oncology therapies. The company is working on several clinical and preclinical assets, including Varegacestat and IM-1021, targeting various tumors. Led by CEO Dr. Clay B. Siegall, Immunome employs around 206 people.

Bottom Line

Max Rosett's planned sale of 60,000 shares of Immunome is part of routine insider trading activity. Immunome, known for its innovative oncology solutions, continues to attract institutional interest, as seen in recent position changes by major funds. Keep in mind that 13F filings and insider transactions provide a backward-looking view of holdings and activity.